Home > Analytics > MARKSANS PHARMA

MARKSANS PHARMA
Intrinsic Value | Fundamental Analysis

BOM : 524404     NSE : MARKSANS    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 07,2023
Price(EOD): ₹ 89.32
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 4,047.98 Cr
Value of ₹ 1 Lac invested in MARKSANS PHARMA
on Jun 07,2018 (price: ₹ 26.65)

₹ 1 L

₹ 3.35 L

1W : 6.2% 1M : 17.1% 1Y : 89.8%
COMMUNITY POLL
for MARKSANS PHARMA
Please provide your vote to see the results
MARKSANS PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
Industry Peers & Returns1W1M1Y
MARKSANS PHARMA 6.2% 17.1% 89.8%
SUN PHARMACEUTICAL INDUSTRIES 2.7% 5.9% 17.9%
DIVIS LABORATORIES 0.5% 4.8% 0.3%
CIPLA -0.4% 2.3% -1.5%
DR REDDYS LABORATORIES 2.6% -5.3% 7%
TORRENT PHARMACEUTICALS 1.5% 9.3% 27.1%
ABBOTT INDIA 1.3% -0.2% 18.8%
ZYDUS LIFESCIENCES 0.3% -1.9% 41.3%
ALKEM LABORATORIES 0.8% -5.8% 9.5%

FUNDAMENTAL ANALYSIS OF MARKSANS PHARMA

 
Fundamentals Score
[ Q(TTM): Mar2023, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 MARKSANS is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF MARKSANS PHARMA

 
Valuation Score
[As on : Jun 07,2023 ]

Ratio Consolidated
P/E
P/B
P/S
15.26
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 265.32 Cr
[Latest Qtr - Mar2023 - Consolidated Results ]

2.32
P/B Calculated based on Book Value of Rs 1,745.16 Cr
[Latest Year - Mar2023 - Consolidated Results ]

2.19
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,852.14 Cr
[Latest Qtr - Mar2023 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 23% undervalued companies ! Discover More →

FAIR VALUE OF MARKSANS PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-9%
17%
46%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF MARKSANS PHARMA


Insights 💡 MARKSANS is one of the top 48% companies with bullish price momentum currently! Discover More →

MARKSANS PHARMA vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF MARKSANS PHARMA

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.01
0
0
-
0.04
0.02
0.03
0.03
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF MARKSANS PHARMA

Pledged Promoter Shares
0 %
As on : Mar2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF MARKSANS PHARMA

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
1.28%
42.93%
31.53%
32.75%
16.25%
72.14%
98.05%
178.93%
QtrlyTrend
8
Latest Qtr: Mar2023
Quarterly Result Analysis →


MARKSANS PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE SMALL CAP 3.3% 7.1% 18.8%
S&P BSE HEALTHCARE 3.2% 5.1% 10%
S&P BSE MIDSMALLCAP 2.9% 6.7% 19.4%
S&P BSE ALLCAP 1.6% 3.9% 13.8%
No NSE index found

You may also like the below Video Courses


FAQ about MARKSANS PHARMA


Is MARKSANS PHARMA good for long term investment?

As on Jun 07,2023, the Fundamentals of MARKSANS PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MARKSANS PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is MARKSANS PHARMA UnderValued or OverValued?

As on Jun 07,2023, MARKSANS PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of MARKSANS PHARMA ?

As on Jun 07,2023, the Intrinsic Value of MARKSANS PHARMA is Rs. 76.30 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 98.65
Fair Value [Median EV / Sales Model] : Rs. 76.30
Fair Value [Median Price / Sales Model] : Rs. 61.01
Estimated Median Fair Value of MARKSANS PHARMA : Rs. 76.30

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is MARKSANS PHARMA trading at a Premium or Discount?

As on Jun 07,2023, MARKSANS PHARMA is trading at a Premium of 17% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].